BRPI0517967A - anticorpos contra tenascina-c - Google Patents

anticorpos contra tenascina-c

Info

Publication number
BRPI0517967A
BRPI0517967A BRPI0517967-0A BRPI0517967A BRPI0517967A BR PI0517967 A BRPI0517967 A BR PI0517967A BR PI0517967 A BRPI0517967 A BR PI0517967A BR PI0517967 A BRPI0517967 A BR PI0517967A
Authority
BR
Brazil
Prior art keywords
tenascin
domain
specific binding
binding members
antibodies
Prior art date
Application number
BRPI0517967-0A
Other languages
English (en)
Inventor
Simon Brack
Michela Silacci
Dario Neri
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Publication of BRPI0517967A publication Critical patent/BRPI0517967A/pt
Publication of BRPI0517967B1 publication Critical patent/BRPI0517967B1/pt
Publication of BRPI0517967B8 publication Critical patent/BRPI0517967B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

ANTICORPOS CONTRA TENASCINA-C.Membros de ligação específicos contra proteína de matriz ex-tracelular tenascina-U, especialmente moléculas de anticorpo de scFv contra domínio A1, domínio C e domínio D de tenascina-C. Membros de ligação específicos de antitenascina-C conjugados com marcações, moléculas citotóxicas ou citocinas. Uso dos membros de ligação específicos de antitenascina-C em diagnose e tratamento, especialmente de câncer.
BRPI0517967A 2004-11-09 2005-10-31 anticorpo isolado que liga-se a tenascina-c humana BRPI0517967B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62617304P 2004-11-09 2004-11-09
US60/626,173 2004-11-09
US67737605P 2005-05-03 2005-05-03
US60/677,376 2005-05-03
PCT/EP2005/011624 WO2006050834A2 (en) 2004-11-09 2005-10-31 Antibodies against tenascin-c

Publications (3)

Publication Number Publication Date
BRPI0517967A true BRPI0517967A (pt) 2008-10-28
BRPI0517967B1 BRPI0517967B1 (pt) 2020-09-15
BRPI0517967B8 BRPI0517967B8 (pt) 2021-05-25

Family

ID=36336853

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517967A BRPI0517967B8 (pt) 2004-11-09 2005-10-31 anticorpo isolado que liga-se a tenascina-c humana

Country Status (20)

Country Link
US (1) US7968685B2 (pt)
EP (2) EP2157102A1 (pt)
JP (2) JP2008518609A (pt)
KR (1) KR20070085892A (pt)
CN (1) CN101090913B (pt)
AT (1) ATE432293T1 (pt)
AU (1) AU2005304031B2 (pt)
BR (1) BRPI0517967B8 (pt)
CA (1) CA2586661A1 (pt)
CY (1) CY1110481T1 (pt)
DE (1) DE602005014665D1 (pt)
DK (1) DK1817345T3 (pt)
EA (1) EA013537B1 (pt)
ES (1) ES2327349T3 (pt)
HK (1) HK1115756A1 (pt)
MX (1) MX2007005582A (pt)
PL (1) PL1817345T3 (pt)
PT (1) PT1817345E (pt)
SI (1) SI1817345T1 (pt)
WO (1) WO2006050834A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
WO2007056441A2 (en) * 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
JP5221641B2 (ja) 2007-04-02 2013-06-26 フィロゲン エスピーエー 腫瘍転移の血管新生と関連するフィブロネクチンのｅｄ−ａ抗原
MX2009013752A (es) * 2007-06-28 2010-02-01 Philogen Spa Inmunocitocinas para el tratamiento del cancer en combinacion con agentes quimioterapeuticos.
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
WO2009056268A1 (en) 2007-10-30 2009-05-07 Philogen S.P.A. An antigen associated with rheumatoid arthritis
WO2009089998A1 (en) * 2008-01-15 2009-07-23 Philochem Ag Binding members for tenascin-c domain a2
US8580267B2 (en) 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
CA2748401C (en) 2009-01-07 2017-09-12 Philogen S.P.A. Antigens associated with endometriosis
EP2448599A1 (en) 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
EP2461832B1 (en) 2009-08-05 2017-06-28 Philogen S.p.A. Targeting of bone marrow neovasculature
WO2011107586A1 (en) * 2010-03-05 2011-09-09 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, Smoc1, tenascin-c and brain cancers
RU2584597C2 (ru) 2010-08-13 2016-05-20 Рош Гликарт Аг Антитела против а2 тенасцина с и способы их применения
WO2013010749A1 (en) 2011-07-19 2013-01-24 Philogen S.P.A Sequential anti - ctla4 and targeted il-2 therapy
EP2736535B1 (en) 2011-07-27 2018-10-17 Philogen S.p.A. Il-12 immunoconjugate
JP6241912B2 (ja) * 2012-04-27 2017-12-06 国立研究開発法人量子科学技術研究開発機構 核医学診断装置の制御方法、核医学診断装置、および診断剤キット
DK2903629T3 (da) 2012-10-03 2019-08-05 Philogen Spa Antistofkonjugat til anvendelse ved behandling af inflammatorisk tarmsygdom
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
WO2015114166A2 (en) * 2014-02-03 2015-08-06 Philochem Ag Targeted drug conjugates
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3387016A1 (en) 2015-12-11 2018-10-17 Philogen S.p.A. Antibodies for treatment and diagnosis of inflammatory bowel disease
ES2864095T3 (es) 2016-04-15 2021-10-13 Philogen Spa Anticuerpo anti-tenascina no glicosilado
CN109071652B (zh) 2016-05-11 2022-09-23 豪夫迈·罗氏有限公司 包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
WO2017194441A1 (en) * 2016-05-11 2017-11-16 F. Hoffmann-La Roche Ag Modified anti-tenascin antibodies and methods of use
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
AU2017358578B2 (en) 2016-11-09 2022-12-08 Philogen S.P.A IL2 and TNF mutant immunoconjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3601346A1 (en) 2017-03-29 2020-02-05 H. Hoffnabb-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018224550A1 (en) 2017-06-07 2018-12-13 Philogen S.P.A Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
US20220119450A1 (en) 2019-02-04 2022-04-21 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
WO2022073038A1 (en) 2020-10-02 2022-04-07 Abbvie Inc. Interleukin-22 (il-22) fusion proteins and uses thereof
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
IT1307864B1 (it) * 1999-04-20 2001-11-19 Istituto Naz Per La Ricerca Su Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
WO2001062800A1 (en) * 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
JP5127085B2 (ja) 2013-01-23
PL1817345T3 (pl) 2009-10-30
AU2005304031B2 (en) 2009-04-23
BRPI0517967B1 (pt) 2020-09-15
DK1817345T3 (da) 2009-09-28
CY1110481T1 (el) 2015-04-29
CA2586661A1 (en) 2006-05-18
MX2007005582A (es) 2007-09-11
US20080056997A1 (en) 2008-03-06
DE602005014665D1 (de) 2009-07-09
WO2006050834A3 (en) 2007-02-08
EA013537B1 (ru) 2010-06-30
CN101090913B (zh) 2015-11-25
WO2006050834A2 (en) 2006-05-18
AU2005304031A1 (en) 2006-05-18
SI1817345T1 (sl) 2009-10-31
EP1817345A2 (en) 2007-08-15
EP1817345B1 (en) 2009-05-27
EP1817345B9 (en) 2009-11-18
ES2327349T3 (es) 2009-10-28
US7968685B2 (en) 2011-06-28
HK1115756A1 (zh) 2008-12-05
EP2157102A1 (en) 2010-02-24
PT1817345E (pt) 2009-08-21
ATE432293T1 (de) 2009-06-15
EA200700991A1 (ru) 2007-12-28
JP2012176957A (ja) 2012-09-13
KR20070085892A (ko) 2007-08-27
JP2008518609A (ja) 2008-06-05
CN101090913A (zh) 2007-12-19
BRPI0517967B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
BRPI0517967A (pt) anticorpos contra tenascina-c
DE602006016344D1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate, die diese enthalten
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
CY1119102T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεισαυτων
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
NZ592215A (en) c-MET ANTIBODIES
RS53168B (en) Antibodies and Immunoconjugates and Their Use
WO2008065378A3 (en) Binding members for interleukin-6
BRPI0918555A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
BRPI0918739A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição.
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EP2192132A3 (en) Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
BRPI0912570B8 (pt) anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos
WO2007067984A3 (en) Neutralizing antibodies against primate psgl-1 and uses therefor
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2642 DE 24-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.